ADHD

Using Combined Data from Clinicians and Their Patients to Evaluate Effectiveness of ADHD Education.
Johnson MD, Salinas G, Tordoff S. Poster presented at the 36th Annual Conference of the Alliance for CME. January 26-29, 2011; San Francisco, CA. Abstract P20.

Bipolar Disorder

Simplified Model for Educational Outcomes Measurements: Change in Serum Lipid Monitoring Rates in Patients with Bipolar Disorder or Schizophrenia.
Leffler JB, Johnson MD, Keck PE. Presented at the 37th Annual Conference of the Alliance for Continuing Education in the Health Professions; January 21–24, 2012; Orlando, FL.

Clinician Education Improves Lipid Monitoring in Patients Taking Second-Generation Antipsychotic Agents, Nationally and Locally
Binford SH, Johnson MD, Kennedy RS, Leffler JB; and CME Outfitters. Health Outcomes Res Med. 2012:3(3):e121-e137. doi:10.1016/j.ehrm.2012.05.002. Epub 2012 Jun 8.

Continuing Medical Education Outcomes Report on the Effectiveness of a Multimedia Activity on Bipolar Depression: Differential Diagnosis and Initial Treatment for Better Patient Outcomes

Chair Summit

Ask-The-Expert Meets Peer-To-Peer: Outcomes from the 3rd Annual Chair Summit: The Master Class for Neuroscience Professional Development, August 26–29, 2010, Chicago, IL.
Ansted CA, Kennedy RS, Schultz J. Presented at: 37th Annual Conference of the Alliance for Continuing Education in the Health Professions; January 21–24, 2012; Orlando, FL.

Outcomes and Analysis from the 2nd Annual Chairs in Psychiatry Summit
The Master Class for Psychiatric Professional Development, Charleston, SC July 16-19, 2009

Schizophrenia

Issues of Adherence in Treating – Individuals With Schizophrenia
Clinicians Overrated their pre-activity competence in managing schizophrenia and learned they needed to both improve practices regarding medication adherence and optimize treatment with new strategies to prevent relapse within the first year and beyond.

Educational Outcomes and Analysis: Schizophrenia and Approaches to Recovery
Clinicians find new “optimism” in developing multimodal schizophrenia treatment plans with a goal of “recovery” that does not indicate “failure” when the expected relapse of schizophrenia occurs.